Stakeholders must navigate these changes carefully, as compliance will be essential for maintaining market presence and consumer trust
Similar content being viewed by others Introduction Tobacco use is recognized as a leading cause of preventable death in many countries as using combustible tobacco products is associated with pulmonary disease, cardiovascular disease, and other forms of chronic illness [1]
The 11 DSM-5 diagnostic criteria for stimulant use disorder are: Taking stimulants in larger amounts or for longer than intended A persistent desire or unsuccessful efforts to reduce or control stimulant use Spending a great deal of time obtaining, using, or recovering from stimulants Strong craving or urge to use stimulants Failing to fulfill major obligations at work, school, or home because of stimulant use Continuing use despite persistent or recurring interpersonal or social problems caused by stimulants Giving up or reducing important social, work, or recreational activities because of stimulant use Repeatedly using stimulants in physically hazardous situations Continuing use despite knowing stimulants are worsening a physical or psychological condition Tolerance: needing significantly more of the drug to achieve the same effect Withdrawal: experiencing characteristic withdrawal symptoms when reducing or stopping use Severity is classified by the number of criteria met: Mild: 2 to 3 criteria Moderate: 4 to 5 criteria Severe: 6 or more criteria It is important to note that developing tolerance or experiencing withdrawal during prescribed, closely supervised medical use does not automatically constitute a use disorder
Smoking also decreases maternal milk supply, likely through the effect of nicotine, which lowers serum prolactin levels
